Experiences with a new ergoline (CF 25-397) in parkinsonism

Paul F. Teychenne, Ronald Pfeiffer, Stanley M. Bern, Donald B. Calne

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Studies on rats with unilateral nigral lesions suggest that a new ergoline, CF 25-397, is a dopaminergic agonist that might improve parkinsonism. CF 25-397 induces less stereotyped behavior than other dopaminergic agents in rats, and might therefore cause less dyskinesia than levodopa in man. We investigated the clinical actions of CF 25-397 in nine patients. During treatment, severe deterioration resulted in hypokinesia and rigidity; five patients showed marked dysphagia and dysphonia. There was statistically significant deterioration in four timed tests. Mild improvement, not statistically significant, was noted in tremor. These results indicate that clinical implication of the response to potential therapeutic agents in rodent models of parkinsonism must be interpreted with caution.

Original languageEnglish (US)
Pages (from-to)1140-1143
Number of pages4
JournalNeurology
Volume27
Issue number12
StatePublished - 1977
Externally publishedYes

Fingerprint

Ergolines
Parkinsonian Disorders
Stereotyped Behavior
Dysphonia
Hypokinesia
Dopamine Agents
Dopamine Agonists
Dyskinesias
Levodopa
Tremor
Substantia Nigra
Deglutition Disorders
Rodentia
Therapeutics
Rat
Deterioration

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Teychenne, P. F., Pfeiffer, R., Bern, S. M., & Calne, D. B. (1977). Experiences with a new ergoline (CF 25-397) in parkinsonism. Neurology, 27(12), 1140-1143.

Experiences with a new ergoline (CF 25-397) in parkinsonism. / Teychenne, Paul F.; Pfeiffer, Ronald; Bern, Stanley M.; Calne, Donald B.

In: Neurology, Vol. 27, No. 12, 1977, p. 1140-1143.

Research output: Contribution to journalArticle

Teychenne, PF, Pfeiffer, R, Bern, SM & Calne, DB 1977, 'Experiences with a new ergoline (CF 25-397) in parkinsonism', Neurology, vol. 27, no. 12, pp. 1140-1143.
Teychenne PF, Pfeiffer R, Bern SM, Calne DB. Experiences with a new ergoline (CF 25-397) in parkinsonism. Neurology. 1977;27(12):1140-1143.
Teychenne, Paul F. ; Pfeiffer, Ronald ; Bern, Stanley M. ; Calne, Donald B. / Experiences with a new ergoline (CF 25-397) in parkinsonism. In: Neurology. 1977 ; Vol. 27, No. 12. pp. 1140-1143.
@article{aeeb0ea8396044bca68547f84659d1d9,
title = "Experiences with a new ergoline (CF 25-397) in parkinsonism",
abstract = "Studies on rats with unilateral nigral lesions suggest that a new ergoline, CF 25-397, is a dopaminergic agonist that might improve parkinsonism. CF 25-397 induces less stereotyped behavior than other dopaminergic agents in rats, and might therefore cause less dyskinesia than levodopa in man. We investigated the clinical actions of CF 25-397 in nine patients. During treatment, severe deterioration resulted in hypokinesia and rigidity; five patients showed marked dysphagia and dysphonia. There was statistically significant deterioration in four timed tests. Mild improvement, not statistically significant, was noted in tremor. These results indicate that clinical implication of the response to potential therapeutic agents in rodent models of parkinsonism must be interpreted with caution.",
author = "Teychenne, {Paul F.} and Ronald Pfeiffer and Bern, {Stanley M.} and Calne, {Donald B.}",
year = "1977",
language = "English (US)",
volume = "27",
pages = "1140--1143",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Experiences with a new ergoline (CF 25-397) in parkinsonism

AU - Teychenne, Paul F.

AU - Pfeiffer, Ronald

AU - Bern, Stanley M.

AU - Calne, Donald B.

PY - 1977

Y1 - 1977

N2 - Studies on rats with unilateral nigral lesions suggest that a new ergoline, CF 25-397, is a dopaminergic agonist that might improve parkinsonism. CF 25-397 induces less stereotyped behavior than other dopaminergic agents in rats, and might therefore cause less dyskinesia than levodopa in man. We investigated the clinical actions of CF 25-397 in nine patients. During treatment, severe deterioration resulted in hypokinesia and rigidity; five patients showed marked dysphagia and dysphonia. There was statistically significant deterioration in four timed tests. Mild improvement, not statistically significant, was noted in tremor. These results indicate that clinical implication of the response to potential therapeutic agents in rodent models of parkinsonism must be interpreted with caution.

AB - Studies on rats with unilateral nigral lesions suggest that a new ergoline, CF 25-397, is a dopaminergic agonist that might improve parkinsonism. CF 25-397 induces less stereotyped behavior than other dopaminergic agents in rats, and might therefore cause less dyskinesia than levodopa in man. We investigated the clinical actions of CF 25-397 in nine patients. During treatment, severe deterioration resulted in hypokinesia and rigidity; five patients showed marked dysphagia and dysphonia. There was statistically significant deterioration in four timed tests. Mild improvement, not statistically significant, was noted in tremor. These results indicate that clinical implication of the response to potential therapeutic agents in rodent models of parkinsonism must be interpreted with caution.

UR - http://www.scopus.com/inward/record.url?scp=0017573688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017573688&partnerID=8YFLogxK

M3 - Article

C2 - 563012

AN - SCOPUS:0017573688

VL - 27

SP - 1140

EP - 1143

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 12

ER -